Technical Analysis for APLS - Apellis Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
24.21 | 4.81% | 1.11 |
APLS closed up 4.81 percent on Tuesday, June 19, 2018, on approximately normal volume. It was able to find support at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | N/A | Up | Up |
| See historical APLS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jun 19 | 50 DMA Support | Bullish | 0.00% |
| Jun 19 | MACD Bullish Centerline Cross | Bullish | 0.00% |
| Jun 19 | Outside Day | Range Expansion | 0.00% |
| Jun 19 | Above Upper BB | Strength | 0.00% |
| Jun 19 | Overbought Stochastic | Strength | 0.00% |
| Jun 19 | Up 3 Days in a Row | Strength | 0.00% |
| Jun 19 | Up 4 Days in a Row | Strength | 0.00% |
| Jun 19 | Up 5 Days in a Row | Strength | 0.00% |
| Jun 19 | Upper Bollinger Band Touch | Strength | 0.00% |
| Jun 18 | Crossed Above 50 DMA | Bullish | 4.81% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
- Sector: Healthcare
- Industry: Biopharmaceuticals
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more APLS news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 32.0 |
| 52 Week Low | 12.45 |
| Average Volume | 426,318 |
| 200-Day Moving Average | 0.0 |
| 50-Day Moving Average | 23.1201 |
| 20-Day Moving Average | 20.9223 |
| 10-Day Moving Average | 21.6235 |
| Average True Range | 1.5675 |
| ADX | 15.5 |
| +DI | 27.12 |
| -DI | 13.67 |
| Chandelier Exit (Long, 3 ATRs ) | 20.2175 |
| Chandelier Exit (Short, 3 ATRs ) | 23.5925 |
| Upper Bollinger Band | 23.3282 |
| Lower Bollinger Band | 18.5164 |
| Percent B (%b) | 1.18 |
| BandWidth | 22.998428 |
| MACD Line | 0.0428 |
| MACD Signal Line | -0.4518 |
| MACD Histogram | 0.4946 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 27.17 | ||||
| Resistance 3 (R3) | 26.86 | 25.58 | 26.67 | ||
| Resistance 2 (R2) | 25.58 | 24.82 | 25.73 | 26.51 | |
| Resistance 1 (R1) | 24.89 | 24.36 | 25.24 | 25.20 | 26.34 |
| Pivot Point | 23.61 | 23.61 | 23.78 | 23.76 | 23.61 |
| Support 1 (S1) | 22.92 | 22.85 | 23.27 | 23.23 | 22.08 |
| Support 2 (S2) | 21.64 | 22.39 | 21.79 | 21.91 | |
| Support 3 (S3) | 20.95 | 21.64 | 21.75 | ||
| Support 4 (S4) | 21.26 |
